Form 8-K - Current report:
SEC Accession No. 0001193125-24-217822
Filing Date
2024-09-12
Accepted
2024-09-12 12:43:53
Documents
15
Period of Report
2024-09-12
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d844807d8k.htm   iXBRL 8-K 25235
2 EX-99.1 d844807dex991.htm EX-99.1 16822
6 GRAPHIC g844807snap1.jpg GRAPHIC 8114
  Complete submission text file 0001193125-24-217822.txt   182388

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fulc-20240912.xsd EX-101.SCH 2856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fulc-20240912_lab.xml EX-101.LAB 17978
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fulc-20240912_pre.xml EX-101.PRE 11262
17 EXTRACTED XBRL INSTANCE DOCUMENT d844807d8k_htm.xml XML 3636
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

EIN.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38978 | Film No.: 241294410
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)